MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Castle Biosciences Interest Expense 2011-2025 | CSTL
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Castle Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1 K | 2.63 M | 4.57 M | 2.27 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.57 M | 1 K | 2.37 M |
Quarterly Interest Expense Castle Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48 K | 9 K | 8 K | - | 192 K | 216 K | 12 K | - | 2 K | 3 K | 4 K | - | 6 K | 4 K | 3 K | - | - | - | - | - | 706 K | 769 K | 764 K | - | 1.09 M | 1.69 M | 1.02 M | - | 569 K | 525 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.69 M | 2 K | 382 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.9 | 7.3 % | $ 183 M |  China |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.57 | -3.08 % | $ 2 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 12.0 | 0.93 % | $ 340 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
20.3 M | $ 66.39 | -0.85 % | $ 25.6 B | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 226.5 | - | $ 166 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.57 | 0.07 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 26.81 | -1.22 % | $ 811 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 19.74 | -3.99 % | $ 1.06 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 102.0 | -3.09 % | $ 4.02 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.53 | -1.4 % | $ 113 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 0.31 | -9.4 % | $ 9.1 M | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 222.3 | 0.04 % | $ 40.3 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 103.47 | 1.37 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 133.88 | -0.73 % | $ 21.3 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 196.14 | 1.64 % | $ 10.1 B | USA |
 |
Quotient Limited
QTNT
|
2.72 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 183.36 | 0.47 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 7.56 | -3.63 % | $ 980 M | USA |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 410.24 | 1.17 % | $ 29.9 B | Schweiz |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 262.29 | -0.71 % | $ 22 B | USA |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 7.01 | -2.84 % | $ 635 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 183.39 | -1.71 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 701.16 | -0.43 % | $ 57.8 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 67.34 | 1.08 % | $ 4.66 B | USA |
 |
NeoGenomics
NEO
|
-379 K | $ 12.07 | 1.81 % | $ 1.53 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 6.8 | -0.95 % | $ 1.47 B | USA |
 |
Agilent Technologies
A
|
81 M | $ 140.63 | 0.69 % | $ 42.8 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.56 | 0.29 % | $ 5.88 M | USA |
 |
Bioventus
BVS
|
1.29 M | $ 7.59 | 0.53 % | $ 475 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |